Breast cancer in 2017

Spurring science, marking progress, and influencing history

Data published in 2017 underscore the benefit of optimizing anti-HER2 therapy in early stage high-risk HER2-positive disease, and of capecitabine in patients with residual disease after optimal neoadjuvant therapy. In the advanced-stage setting, endocrine therapy combined with cyclin-dependent kinase 4/6 inhibitors, or olaparib could become the preferred option.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    von Minckwitz, G. et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N. Engl. J. Med. 377, 122–131 (2017).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. 2

    Toi, M., Masuda, N. & Ohashi, Y. Adjuvant capecitabine for breast cancer. N. Engl. J. Med. 377, 791–792 (2017).

    PubMed  Google Scholar 

  3. 3

    Haller, D. G. et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J. Clin. Oncol. 26, 2118–2123 (2008).

    CAS  Article  PubMed  Google Scholar 

  4. 4

    Sledge, G. W. et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2 advanced breast cancer who had progressed while receiving endocrine therapy. J. Clin. Oncol. 35, 2875–2884 (2017).

    CAS  Article  PubMed  Google Scholar 

  5. 5

    Goetz, M. P. et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J. Clin. Oncol. 35, 3638–3646 (2017).

    CAS  Article  PubMed  Google Scholar 

  6. 6

    Robson, M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377, 523–533 (2017).

    CAS  Article  PubMed  Google Scholar 

  7. 7

    Rafii, S. et al. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. Oncotarget 8, 47154–47160 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  8. 8

    Rugo, H. S. et al. Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial. JAMA 317, 37–47 (2017).

    CAS  Article  PubMed  Google Scholar 

  9. 9

    Stebbing, J. et al. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncol. 18, 917–928 (2017).

    CAS  Article  PubMed  Google Scholar 

  10. 10

    Finn, R. S. et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 375, 1925–1936 (2016).

    CAS  Article  PubMed  Google Scholar 

  11. 11

    Hortobagyi, G. N. et al. Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2), advanced breast cancer (ABC) [abstract]. J. Clin. Oncol. 35 (Suppl.), 1038 (2017).

    Article  Google Scholar 

  12. 12

    Hortobagyi, G. N. et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N. Engl. J. Med. 375, 1738–1748 (2016).

    CAS  Article  Google Scholar 

  13. 13

    Cristofanilli, M. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 17, 425–439 (2016).

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

J.P-G. and J.C. would like to thank the whole editorial team at Nature Reviews Clinical Oncology for the editing process.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Javier Cortes.

Ethics declarations

Competing interests

J.P-G. declares no competing interests. J.C. has received honoraria from Eisai, Novartis, and Pfizer, and is a consultant and/or adviser for AstraZeneca Biothera, Celgene, Cellestia Biotech, Merus and Roche.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Perez-Garcia, J., Cortes, J. Spurring science, marking progress, and influencing history. Nat Rev Clin Oncol 15, 79–80 (2018). https://doi.org/10.1038/nrclinonc.2017.191

Download citation

Further reading

Search

Quick links

Sign up for the Nature Briefing newsletter for a daily update on COVID-19 science.
Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing